January 22nd, 2012, by David Pascoe | clinical trials, galderma, metrogel
A recently posted clinical trial suggests that Taro Pharmaceuticals is readying to gain approval to market Generic Metrogel 1%. Currently Generic Metrogel is only available in 0.75% strength. Taro Pharmaceuticals in fact already markets a generic form of Metrogel – Metronidazole Gel USP, 0.75% When the patent covering Metrogel 0.75% expired, Galderma changed the formulation, increased the concentration of metronidazole to 1% …
January 18th, 2012, by David Pascoe | metrogel
Galderma have announced that Metrogel 1% will now be available in a 55gm Pump. Galderma are citing the benefits of a better looking dispenser, minimizing waste, easier compliance with prescribing instructions and “facilitating product handling”. Galderma received FDA …
December 18th, 2011, by David Pascoe | galderma, metrogel
Galderma has another rosacea-targeted treatment, until now undisclosed, in the final stages of approval. Hey – how come no one told me?
Could it be possible that the rosacea heavyweight Galderma has kept a new product so secret?
What is this CD5024?
Just what exactly is this CD5024 1% Cream? Galderma …
October 12th, 2011, by David Pascoe | galderma, metrogel
A recently updated patent application by Galderma shows that they want to reserve the right to create a Metronidazole Foam product.
Galderma has a long history with topical metronidazole products, starting with Metrogel 0.75%, then adding Metrolotion and Metrocream, and when the patent on the 0.7% Metrogel expired, Galderma created Metrogel 1%.
Past research seems to suggest that it matters little whether you use Metrogel, Metrolotion, …
July 15th, 2011, by David Pascoe | finacea, metrogel, oracea
A systematic review of the available rosacea research confirms that Metrogel, Finacea and Oracea are effective for moderate to severe rosacea. One study further found cyclosporine 0.05% ophthalmic emulsion effective for ocular rosacea. This review looked at the published results of 58 trials to note bias and construct a high level summary of the results. No Surprises Here It will come as …
